Exudative retinal astrocytic hamartoma diagnosed and treated with pars plana vitrectomy and intravitreal bevacizumab.
M
M
Nakayama
H
H
Keino
A
A
Hirakata
A A
AA
Okada
Y
Y
Terado
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001253:Astrocytes / Q000473:pathology; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000378:metabolism; D003131:Combined Modality Therapy; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006222:Hamartoma / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D009457:Neuroglia / Q000473:pathology; D012164:Retinal Diseases / Q000175:diagnosis* / Q000628:therapy*; D015861:Retinal Neovascularization / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014821:Vitrectomy; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D005904:Glial Fibrillary Acidic Protein; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab